RecruitingNot applicableNCT05579548
A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding
Studying Disorder of phenylalanine metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Principal Investigator
- Medical Director, MD, M.DBioMarin Pharmaceutical
- Intervention
- Pegvaliase(drug)
- Enrollment
- 50 enrolled
- Eligibility
- FEMALE
- Timeline
- 2022 – 2032
Study locations (4)
- Syneos Health, Wilmington, North Carolina, United States
- Metabolics and Genetics in Calgary (MAGIC), Calgary, Canada
- Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany
- Ospedale San Paolo, Milan, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05579548 on ClinicalTrials.govOther trials for Disorder of phenylalanine metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07220265Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU CarriersUniversity of Missouri-Columbia
- RECRUITINGPHASE2NCT06637514A Phase 2 Study of JNT-517 in Adolescent Participants With PhenylketonuriaOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE3NCT06628128A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With PhenylketonuriaOtsuka Pharmaceutical Development & Commercialization, Inc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04480567AAV Gene Therapy Study for Subjects with PKUBioMarin Pharmaceutical